"Odds are low that we would see Lotronex reintroduced because of the pretty high standard that the FDA is imposing on the predictability of side effects," GSK CEO Garnier says. FDA wants company to find a way to identify patients who are at risk for ischemic colitis and severe constipation (1"The Pink Sheet" April 23, p. 10). "We know for a fact that there's no easy way to predict who might suffer from an episode of colitis and who might not. When you look at the few cases we have had, there's no pattern," Garnier says. "So I'm not too optimistic, but we're still in discussions"
You may also be interested in...
GlaxoSmithKline and FDA are discussing ways to identify risk factors for Lotronex adverse events as a foundation for a risk management plan for the irritable bowel syndrome therapy.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials